New Staging System and Prognostic Model for Malignant Phyllodes Tumor Patients without Distant Metastasis: A Development and Validation Study

Ruan, Zhaohui; Quan, Qi; Wang, Qianyu; Jiang, Jiaxin; Peng, Roujun

doi:10.3390/jcm12051889

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mathematical methods and hypotheses, as well as computational modeling to describe PPI and gene regulatory networks, are also constantly improving [134][135][136][137][138]. The philosophical underpinning of how the transition from a normal state to a malignant state can be accurately described in mathematical terms is a subject that merits contemplation [139][140][141]. Furthermore, there is a gradual integration of other molecular entities, such as non-coding RNAs (ncRNAs), into these networks [142,143].…”

Section: Discussionmentioning

confidence: 99%

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

Carels,

Sgariglia,

Junior

et al. 2023

IJMS

View full text Add to dashboard Cite

We describe a strategy for the development of a rational approach of neoplastic disease therapy based on the demonstration that scale-free networks are susceptible to specific attacks directed against its connective hubs. This strategy involves the (i) selection of up-regulated hubs of connectivity in the tumors interactome, (ii) drug repurposing of these hubs, (iii) RNA silencing of non-druggable hubs, (iv) in vitro hub validation, (v) tumor-on-a-chip, (vi) in vivo validation, and (vii) clinical trial. Hubs are protein targets that are assessed as targets for rational therapy of cancer in the context of personalized oncology. We confirmed the existence of a negative correlation between malignant cell aggressivity and the target number needed for specific drugs or RNA interference (RNAi) to maximize the benefit to the patient’s overall survival. Interestingly, we found that some additional proteins not generally targeted by drug treatments might justify the addition of inhibitors designed against them in order to improve therapeutic outcomes. However, many proteins are not druggable, or the available pharmacopeia for these targets is limited, which justifies a therapy based on encapsulated RNAi.

show abstract

Section: Discussionmentioning

confidence: 99%

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

Carels,

Sgariglia,

Junior

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In contrast to invasive ductal carcinoma, phyllodes tumors do not have a distinct staging system for patients. 28 Phyllodes tumors are distinguished by their larger size, increased rate of growth, and microscopic findings of stromal hyperplasia and atypia. The World Health Organization (WHO) classifies phyllodes tumors as benign, borderline, or malignant depending on the level of stromal hyperplasia and atypia, with malignant tumors making up 25% of resected tumors.…”

Section: Methodsmentioning

confidence: 99%

Metastatic and Malignant Phyllodes Tumors of the Breast: An Update for Current Management

Goodwin,

Oyinlola,

Palhang

et al. 2023

The American Surgeon™

View full text Add to dashboard Cite

Metastatic, malignant phyllodes tumor (PT) of the breast is a rare and aggressive neoplasm. Currently, there is no agreed upon consensus as to best management practices. A systematic review of literature was conducted investigating surgical, chemotherapeutic, and radiotherapeutic management for metastatic PT. Databases employed to identify articles included Embase, PubMed, and SAGE Journals. Diagnosis of metastatic PT has been of significant difficulty to radiologists as it is often confused with fibroadenomas. Surgically, metastatectomy has been correlated with increased overall survival (of 25.9 versus 9.9 months; P = .01). Radiotherapy has often been associated with palliation and pain control in metastatic, malignant neoplasia. However, one study showed that in malignant PT, radiation was associated with significantly lower rates of local recurrence (OR: 0.048 versus 0.209). Anthracycline containing chemotherapy regimens has been associated with improved overall survival (22.4 months versus 13.2 months; P = .040). Further research must be conducted into this rare malignancy to elucidate accurate diagnosis and care for patients with advanced metastatic or malignant phyllodes tumors.

show abstract

Tumeurs phyllodes borderlines et malignes du sein : du défi anatomopathologique à l’élaboration d’un standard de prise en charge

Neron,

Maran Gonzalez,

Llacer

et al. 2024

Bulletin du Cancer

View full text Add to dashboard Cite

New Staging System and Prognostic Model for Malignant Phyllodes Tumor Patients without Distant Metastasis: A Development and Validation Study

Cited by 5 publications

References 23 publications

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

Metastatic and Malignant Phyllodes Tumors of the Breast: An Update for Current Management

Tumeurs phyllodes borderlines et malignes du sein : du défi anatomopathologique à l’élaboration d’un standard de prise en charge

Contact Info

Product

Resources

About